Table 2.

Unadjusted and adjusted analysis for the association of Lp(a) levels with risk of the study outcomes

Primary composite outcome
	HR	95% CI	p	p for interaction	Adjusted HR	95% CI	p	p for interaction
Overall population	2.134	1.380–3.300	0.001	0.016	1.634	0.896–2.980	0.109	0.042
Patients with diabetes	1.317	0.571–3.035	0.518		1.466	0.732–2.937	0.280
Patients w/o diabetes	2.731	1.655–4.507	< 0.001		2.119	1.087–4.131	0.028
Myocardial infarction
	HR	95% CI	p	p for interaction	Adjusted HR	95% CI	p	p for interaction
Overall population	2.421	1.406–4.170	0.001	0.029	2.057	1.015–4.172	0.046	0.134
Patients with diabetes	1.690	0.661–4.316	0.273		2.003	0.962–1.169	0.063
Patients w/o diabetes	3.104	1.619–5.951	0.001		2.403	1.119–5.162	0.025
All-cause death
	HR	95% CI	p	P for interaction	Adjusted HR	95% CI	p	p for interaction
Overall population	1.937	1.076–3.486	0.027	0.038	1.249	0.636–2.454	0.519	0.094
Patients with diabetes	0.935	0.265–3.294	0.916		0.728	0.228–2.321	0.591
Patients w/o diabetes	2.629	1.371–5.039	0.004		1.936	0.915–4.099	0.084

Cox proportional-hazards regression model for the risk of the association between Lp(a) and the study outcomes; the HR were calculated for Lp(a) continuous values. CI, confidence interval; HR, hazard ratio; Lp(a), lipoprotein(a)